BridgeBio (BBIO) CEO Neil Kumar Sells 44,980 Shares

What Happened

• Kumar Neil (CEO of BridgeBio Pharma, ticker BBIO) sold a total of 44,980 shares in open-market dispositions on August 18–19, 2026, generating aggregate proceeds of approximately $3,727,251. Individual transactions: 1,900 @ $81.15 ($154,184); 17,279 @ $82.21 ($1,420,514); 14,602 @ $82.99 ($1,211,852); 1,199 @ $83.77 ($100,444); 8,100 @ $83.86 ($679,256); 1,800 @ $84.69 ($152,436); 100 @ $85.65 ($8,565). These were sales (not purchases) and therefore not a bullish signal by themselves.

Key Details

• Transaction dates: August 18–19, 2026; Form 4 filed August 20, 2026 (within the standard two-business-day reporting window).
• Prices and proceeds: see per-lot breakdown above; total proceeds ≈ $3.73M.
• 10b5-1 plan: At least some sales were executed pursuant to a Rule 10b5-1 trading plan adopted May 13, 2026 (footnote F1).
• Weighted-price footnotes: Several footnotes (F2–F8) state weighted-average sale-price ranges and note the reporter will provide full per-price breakdowns on request.
• Beneficial ownership notes: The filer disclaims beneficial ownership of certain shares except to the extent of any pecuniary interest (F7); some shares are held in the "NK 2026 GRAT" grantor retained annuity trust (F9).
• Shares owned after transaction: Not specified in the information provided in your excerpt.

Context

• Sales made under a pre-established 10b5-1 plan are generally considered routine and governed by a schedule set before the trades; that can reduce the informational weight of insider sales as a signal of near-term management sentiment.
• These are outright sales (code S) rather than option exercises, gifts, or awards; no purchases or exercises were reported in this filing.
• The filing notes that full detail on the number of shares sold at each separate price is available to the SEC staff, the issuer, or security holders upon request.